【摘要】 目的研究docetaxel和batimastat（BB₉4）对人肺巨细胞癌 （PG ）的作用并与阿霉素做比较。方法和结果docetaxel对PG细胞有明显的细胞毒作用 ,BB₉4则无此作用 ,而且BB₉4体外不能增强docetaxel的细胞毒作用。体内在早期PG瘤裸鼠模型上应用最大耐受量的docetaxel和阿霉素 （iv,q4d×3）、BB₉4（30mg·kg-1,ip,qd×20）,docetaxel联用BB₉4的抑瘤率（97.3 %）大于阿霉素联用BB₉4（86.5 %）、docetaxel（92.0 %）、阿霉素（74.0 %）和BB₉4（31.0 %）。docetaxel对晚期PG瘤也具有明显的抑制作用 ,而且强于阿霉素。结论docetaxel对PG瘤裸鼠模型具有显著抑制作用 ,联用BB₉4可增强docetaxel的抗肿瘤作用。更多还原

【Abstract】 Aim To study the effect of docetaxel alone and in combination with batimastat (BB-94) on human giant cell carcinoma of the lung (PG). Methods and Results Growth curve analysis, MTT assay and clonogenic assay were used to determine the cytotoxic effect of docetaxel or/and BB-94 on PG cell in vitro.The results showed that docetaxel but not BB-94 had a significant cytotoxicity, and the effect of docetaxel was not enhanced by BB-94. In early stage PG tumor model, obvious antitumor effect of docetaxel or doxorubicin doxorubicin given iv at maximum tolerated dose (MTD, docetaxel 20 mg·kg-1, doxorubicin, 6 mg·kg-1) every 4 days for 3 injections (q4d×3), even of BB-94 (30 mg·kg-1,ip,qd×20) was observed. Tumor growth inhibition was greater for Docetaxel-batimastat (97.3 %) than for doxorubicin-batimastat (86.5 %), docetaxel (92.0 %), doxorubicin (74.0 %) and BB-94 (31.0 %). Docetaxel also showed active against advanced stage PG tumor in dose-dependent manner, and was more effective at MTD than doxorubicin with 4/5 regression, 55.8 days tumor growth delay and 2.8 log10 tumor cell kill. Conclusion Docetaxel is an effective cytotoxic new drug against PG tumor, and BB-94 can enchance the antitumor activity of docetaxel.更多还原